RNS & Investor News
Extension of terms for OptiBiome® with OptiPharm
05 August 2020
OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces it has extended the terms of its original exclusive licence agreement for OptiBiome® with OptiPharm Pty Ltd. ("OptiPharm") as announced on 31 March 2020.
The terms of the exclusive licence agreement signed in March 2020 granted OptiPharm exclusive use of the OptiBiome® trademark in Australia, parts of Asia, New Zealand, Middle East, Gulf States and North America. The extension of terms now includes Europe. Market exclusivity remains linked to minimum order quantities.
OptiPharm is a privately owned Australian company and has currently been operating for 24 years. OptiPharm specialises in weight management, nutrition and infant formula, and their products are produced in state of the art Australian manufacturing facilities that are GMP qualified and HACCP certified.
OptiPharm's flagship brand, Optislim, is the #1 Australian weight management brand incorporating shakes, soups and bars available as total (very low calorie diet) or partial (low calorie diet) meal replacements. Optislim is used by consumers throughout Australia, New Zealand, China, shortly the Middle East and the UAE, and is poised for release throughout South East Asia, North America and Europe. Their company owned trademarked brands include:
- Optislim™ - (weight management meal replacements, including shakes, chocolate bars & soups) www.optislim.com.au
- isustain™ - (nutritional meal replacements for Adults, Children & Diabetics) www.isustain.net.au
- OPTI GOLD™ - (infant formula) www.optigold.com.au
Garry McDonald, Managing Director of OptiPharm, commented: "We will shortly be releasing a new range of Optislim products which will include Optibiotix's patented ingredient for weight management and are delighted that Optibiotix has agreed to an extension of terms that provides unrestricted access to additional international markets."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to announce the extension of terms for OptiPharm as it strengthens the commercial relationship between both companies. It is also another important commercial step in bringing OptiBiotix's patented and award-winning, scientifically formulated functional ingredients to global markets with Australia's #1 weight management brand."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
|OptiBiotix Health plc||www.optibiotix.com|
|Stephen O'Hara, Chief Executive||Contact via Walbrook below|
|Cairn Financial Advisers LLP (NOMAD)||Tel: 020 7213 0880|
|Liam Murray / Jo Turner / Ludovico Lazzaretti|
|finnCap (Broker)||Tel: 020 7220 0500|
|Geoff Nash / Kate Bannatyne (Corporate Finance)|
|Camille Gochez (Corporate Broking)|
|Walbrook PR Ltd||Mob: 07876 741 001|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements, and health snacks and food products. The Company's current areas of focus include obesity, digestive health, cardiovascular health, and diabetes.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020